Prostaglandin E

Global Axial Spondyloarthritis (axSpA) Market Spotlight 2021-2031: Marketed & Pipeline Dugs, Clinical Trials, Regulatory Events, Probability of Success, Disease Prevalence, Revenues - ResearchAndMarkets.com

Retrieved on: 
Monday, June 14, 2021
Health, Pharmaceutical, Medical specialties, Clinical medicine, Medicine, Arthritis, Autoimmune diseases, Rheumatology, Ankylosing spondylitis, Axial spondyloarthritis, G protein-coupled receptors, Spondyloarthropathy, Interleukin-1 family, Prostaglandin E

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, and a 10-year disease prevalence forecast, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, interleukin 17, IL-17 receptor, and JAK/STAT.
  • The greatest proportion of industry-sponsored drugs in active clinical development for axSpA are in the NDA/BLA phase.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for ankylosing spondylitis, followed by AbbVie

Axial Spondyloarthritis (axSpA) Market Spotlight, 2020: Key Marketed & Pipeline Drugs, Clinical Trials, Patent Information, 10-Year Disease Prevalence Forecast, Deals, Drug-Specific Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Friday, April 24, 2020
Health, Pharmaceutical, Companies, Health, Prostaglandins, Arthritis, Chemical compounds, Eicosanoids, G protein-coupled receptors, Prostaglandin E, Axial spondyloarthritis, Pfizer, Niacin, AbbVie Inc.

This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, and IL-17.
  • Germany has a substantial lead in the number of axSpA clinical trials globally, while South Korea has the top spot in Asia.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for axSpA, followed by AbbVie

2020 Market Spotlight: Axial Spondyloarthritis (axSpA)

Retrieved on: 
Friday, April 3, 2020
Health, Companies, Medical specialties, Arthritis, Eicosanoids, G protein-coupled receptors, Axial spondyloarthritis, Prostaglandin E, Spondyloarthropathy, Prostaglandin, Pfizer, AbbVie Inc.

DUBLIN, April 3, 2020 /PRNewswire/ -- The "Market Spotlight: Axial Spondyloarthritis (axSpA) 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 3, 2020 /PRNewswire/ -- The "Market Spotlight: Axial Spondyloarthritis (axSpA) 2020" report has been added to ResearchAndMarkets.com's offering.
  • This Market Spotlight report covers the Axial Spondyloarthritis (axSpA) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the axial spondyloarthritis (axSpA) space target tumor necrosis factor-alpha, prostaglandin E receptor 1, prostaglandin E receptor 2, and IL-17.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for axSpA, followed by AbbVie

ADVANZ PHARMA Corp. Limited Closes Acquisition of the Rights to a Portfolio of Alprostadil Products from UCB S.A. for $83 Million

Retrieved on: 
Wednesday, April 1, 2020
Chemical compounds, Prostaglandins, Organic compounds, Chemistry, RTT, Cyclopentanes, Ketones, Prostaglandin E1, Erectile dysfunction, Prostaglandin E, Cash and cash equivalents, Deposit

The Company today paid the purchase price of $83 million1 (75 million), and a deposit for inventory of approximately $13 million, from its cash on hand.

Key Points: 
  • The Company today paid the purchase price of $83 million1 (75 million), and a deposit for inventory of approximately $13 million, from its cash on hand.
  • As of December 31, 2019, ADVANZ PHARMA's cash and cash equivalents balance was $261 million.
  • The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.
  • Combined sales of all alprostadil brands generated approximately $33.3 million in revenue in 2019 in the territories where ADVANZ PHARMA will hold the rights.

ADVANZ PHARMA Corp. Limited Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products From UCB S.A. For Approximately $84 Million

Retrieved on: 
Friday, March 6, 2020
Chemical compounds, Prostaglandins, Organic compounds, Chemistry, Cyclopentanes, Ketones, Prostaglandin E1, RTT, Erectile dysfunction, Prostaglandin E, Advanz Pharma

The transaction has a purchase price of $84 million1 (75 million) and ADVANZ PHARMA intends to pay for the acquisition with cash on hand.

Key Points: 
  • The transaction has a purchase price of $84 million1 (75 million) and ADVANZ PHARMA intends to pay for the acquisition with cash on hand.
  • On closing, ADVANZ PHARMA will also pay a deposit for inventory of approximately $14 million.
  • The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.
  • Combined sales of all alprostadil brands generated approximately $33.3 million in revenue in 2019 in the territories where ADVANZ PHARMA will hold the rights.